Rallybio Executes Reverse Stock Split to Restore Nasdaq Compliance as Complement Dysregulation Program Faces Headwinds

Rallybio Corporation (RLYB), a clinical-stage biotechnology company, has implemented a 1-for-8 reverse stock split effective February 6, 2026, as a critical move to regain listing compliance on the Nasdaq exchange. The action represents a significant milestone—and market reality check—for the company’s efforts to maintain its public trading status after struggling to meet the exchange’s minimum stock price requirements. Following the announcement, RLYB shares declined 10.27% to trade at $0.56, compared to the previous close of $0.63.

The Path to Reverse Stock Split

The reverse stock split became necessary after Rallybio received a Nasdaq warning on February 24, 2025, when its shares traded below $1.00 for 30 consecutive business days. Despite initial efforts to recover, the company missed the first compliance deadline of August 25, 2025. However, Nasdaq granted Rallybio approval to transfer its listing to the Nasdaq Capital Market, providing a 180-day grace period extending the deadline to February 23, 2026. The February 6 reverse split represents management’s response to this tightening regulatory clock.

Computershare Trust Company, N.A. is administering the reverse split as both the exchange agent and transfer agent. Importantly, stockholders who would have received fractional shares will instead be paid cash equivalent to the fair market value of those fractions, as determined by Rallybio’s Board of Directors. This approach eliminates the creation of fractional share positions in the company’s cap table.

Rallybio’s Complement Dysregulation Strategy

At the core of Rallybio’s clinical pipeline is RLYB116, a differentiated C5 inhibitor designed to address complement dysregulation—a condition where the body’s immune complement system becomes overactive or dysregulated. The company’s initial focus targets two serious conditions: immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). Both conditions represent significant unmet medical needs where complement dysregulation plays a central pathogenic role.

This therapeutic focus on complement dysregulation positions Rallybio within a growing competitive landscape of complement-modulating therapies, though clinical and commercial success remains unproven at this stage.

Expanding Beyond Complement Therapy

Complementing its primary complement dysregulation program, Rallybio’s pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody targeting diseases of iron overload. This pipeline diversification represents management’s strategy to develop a multi-asset portfolio addressing hematological and immunological unmet needs.

Strategic Implications

The reverse stock split, while necessary for regulatory compliance, carries implications for existing shareholders. The 1-for-8 consolidation reduces share count but does not alter the underlying economics of the company—each shareholder’s pro-rata ownership stake remains mathematically unchanged, though the reduced float may affect trading dynamics and investor perception.

With the February 23, 2026 final compliance deadline now in the near term, Rallybio faces pressure to either demonstrate tangible clinical progress or continue pursuing additional capital market solutions to sustain its public company status. The biotech sector’s current funding environment adds urgency to these challenges.